Abstract

BackgroundGiant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are strongly overlapping diseases that are thought to have a shared etiology [1]. The observation of varicella-zoster virus (VZV) antigen in temporal...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0522 Vascular and joint inflammation are negatively correlated in patients with polymyalgia rheumatica, giant cell arteritis and fever of unknown origin
M Bauckneht ... M.A Cimmino
Annals of the Rheumatic Diseases | VOL. 77
M Bauckneht, et. al.M Bauckneht ... M.A Cimmino
01 Jun 2018
Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study
C S Crowson ... T A Kermani
Rheumatology | VOL. 49
C S Crowson, et. al.C S Crowson ... T A Kermani
13 Jul 2010
AB0743 THE IMPACT OF GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA ON FRAILTY, DAILY FUNCTIONING AND QUALITY OF LIFE IN A PROSPECTIVE LONGITUDINAL STANDARD-OF-CARE COHORT
S Arends ... M Sandovici
Annals of the Rheumatic Diseases | VOL. 82
S Arends, et. al.S Arends ... M Sandovici
30 May 2023
SAT0030 Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition
J Westra ... Y Van Sleen
Annals of the Rheumatic Diseases | VOL. 75
J Westra, et. al.J Westra ... Y Van Sleen
01 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers